Fwd: Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:52 AM
Subject: Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival.
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 May 27;
Shabo I, Stål O, Olsson H, Doré S, Svanvik J

Cells of the monocyte/macrophage lineage are important for tumour cell migration, invasion and metastasis. Fusion between macrophages and cancer cells in animal models in vitro and in vivo causes hybrids with increased metastatic potential. Primary breast cancer cells were characterized for macrophage antigens to test if phenotypic resemblance to macrophages is related to early distant recurrence. Immunostaining for CD163, MAC387 and CD68 was performed in a breast cancer tissue micro array from 127 patients consequently followed up for a median of 13 years. Tumour-associated macrophages expressed all 3 antigens. The breast cancers expressed CD163 to 48%, MAC387 to 14% while CD68 was not expressed. TGF-beta staining intensity was positively related to both CD163 and MAC387 expression. Expression of CD163 in the cancer cells was compared to their DNA ploidy, Nottingham Histological Grade, TNM-stage, node state, presence of estrogen receptors and occurrence of distant metastases and survival. Cancers of a more advanced histological grade expressed CD163 to a higher extent. Cells expressing MAC387 were more common in cancers with a high proportion of CD163 positive cells. Multivariate analysis showed that expression of the macrophage antigen CD163 in breast cancer cells has a prognostic impact on the occurrence of distant metastases and reduced patient survival time. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18506688
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: K-State to host fund-raising event in Earl Woods' honor Saturday - Wichita Business Journal

---------- Forwarded message ----------
From: asbestos cancer - Live Search News <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:51 AM
Subject: K-State to host fund-raising event in Earl Woods' honor Saturday - Wichita Business Journal
To: mesothelioma77@gmail.com


Delicate Balance [Wichita] KSU's Leasure Hall closed amid concern over asbestos [Wichita] Former regent named chairman of K-State presidential search committee [Wichita] Harris gets $42M Army contract [Orlando] Eagle Group now part of Lockheed Martin ...

Thu, 29 May 2008 21:36:00 GMT

___
Source: http://wichita.bizjournals.com/wichita/stories/2008/05/26/daily23.html
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Radiographer gender and breast-screening uptake.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:52 AM
Subject: Radiographer gender and breast-screening uptake.
To: mesothelioma77@gmail.com


[1]Br J Cancer. 2008 Jun 3; 98(11): 1759-61
Fitzpatrick P, Winston A, Mooney T

BreastCheck, the Irish National Breast Screening Programme, screens women aged 50-64. Radiographer recruitment has been a challenge; doubling of numbers is required for full national expansion; to date females are employed. The aim was to document attitudes to male radiographers and effect on return for subsequent screening. In all 85.8% of a random sample of 2000 women recently screened by BreastCheck completed a postal questionnaire. The commonest reaction women felt they would have if there were a male radiographer was embarrassment; significantly greater among those attending a static unit (45.6%) than mobile (38.4%) and in younger women (46%) than older (38.7%). Nine per cent would not have proceeded if the radiographer was male and 9% would only have proceeded if female chaperone present. In all 17.5% (95% CI 15.7-19.4%) agreed that 'If there were male radiographers I would not return for another screening appointment'; 18.3% were unsure. One-quarter agreed 'if I heard there could be male radiographers it would change my opinion of BreastCheck for the worse'. The proportions agreeing with these statements did not vary significantly by screening unit type, age group, area of residence or insurance status. This is the largest published study to date of this important issue; the correct balance between equality and programme performance must be identified.



___
Source: http://www.hubmed.org/display.cgi?uids=18506178
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Risks and benefits of bisphosphonates.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:52 AM
Subject: Risks and benefits of bisphosphonates.
To: mesothelioma77@gmail.com


[1]Br J Cancer. 2008 Jun 3; 98(11): 1736-40
Coleman RE

Bone is the most common site for metastasis in cancer and is of particular clinical importance in breast and prostate cancers due to the prevalence of these diseases. Bone metastases result in considerable morbidity and complex demands on health care resources, affecting quality of life and independence over years rather than months. The bisphosphonates have been shown to reduce skeletal morbidity in multiple myeloma as well as a wide range of solid tumours affecting bone by 30-50%. Quite appropriately, these agents are increasingly used alongside anticancer treatments to prevent skeletal complications and relieve bone pain. The use of bisphosphonates in early cancer is also increasingly important to prevent the adverse effects of cancer treatments on bone health. These include ovarian suppression and the use of aromatase inhibitors in breast cancer patients and androgen deprivation therapy in those with prostate cancer. Bisphosphonate strategies, similar to those used to treat postmenopausal osteoporosis, have suggested that bisphosphonates are a safe and effective treatment for the prevention of treatment-induced bone loss. When compared to other cancer therapies, the frequency and severity of adverse events related to bisphosphonate therapy are generally mild and infrequent; thus, the benefits of treatment with any bisphosphonate almost always outweigh the risks. However, renal dysfunction may occasionally occur and over recent years, a new entity, bisphosphonate-associated osteonecrosis of the jaw (ONJ), has been described. The incidence, clinical importance and prevention strategies to minimise the impact of this problem on patients requiring bisphosphonates is discussed.



___
Source: http://www.hubmed.org/display.cgi?uids=18506174
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Predictors of breast cancer-related distress following mammography screening in younger women on a family history breast screening programme.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:52 AM
Subject: Predictors of breast cancer-related distress following mammography screening in younger women on a family history breast screening programme.
To: mesothelioma77@gmail.com


[1]Psychooncology. 2008 May 27;
Brain K, Henderson BJ, Tyndel S, Bankhead C, Watson E, Clements A, Austoker J,

Objective: This longitudinal study investigated pre-screening factors that predicted breast cancer-specific distress among 1286 women who were undergoing annual mammography screening as part of a UK programme for younger women (i.e., under 50) with a family history of breast cancer.Methods: Women completed questionnaires one month prior to screening, and one and six months after receiving screening results. Factors measured were breast cancer worry, perceived risk, cognitive appraisals, coping, dispositional optimism, and background variables relating to screening history and family history.Results: Pre-screening cancer worry was the most important predictor of subsequent worry, explaining 56/61% and 54/57% of the variance at one and six months follow-up, respectively. Other salient pre-screening predictors included high perceived risk of breast cancer, appraisals of high relevance and threat associated with the family history, and low perceived ability to cope emotionally. Women who had previously been part of the screening programme and those with a relative who had recently died from breast cancer were also vulnerable to longer-term distress. A false positive screening result, pessimistic personality, and coping efforts relating to religion and substance use predicted outcomes of screening at one month follow-up, but were not predictive in the longer-term.Conclusion: Early intervention to ameliorate high levels of cancer-related distress and negative appraisals would benefit some women as they progress through the familial breast screening programme. Copyright (c) 2008 John Wiley & Sons, Ltd.



___
Source: http://www.hubmed.org/display.cgi?uids=18506670
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:52 AM
Subject: Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.
To: mesothelioma77@gmail.com


[1]Breast Cancer Res Treat. 2008 May 28;
Han HS, Ro J, Lee KS, Nam BH, Seo JA, Lee DH, Lee H, Lee ES, Kang HS, Kim SW

Purpose: Chemotherapy-induced amenorrhea (CIA) by newer taxane-containing regimens was evaluated in early breast cancer (EBC) patients. Methods: A prospective cohort of 122 premenopausal EBC patients participated in a phase III trial of preoperative docetaxel/capecitabine (TX) versus doxorubicin/cyclophosphamide (AC); 34 patients received adjuvant AC followed by paclitaxel (T) and 129 patients received 5-fluorouracil/doxorubicin/cyclophosphamide (FAC). Results: The CIA rate was 90.2% with TX/AC, 73.5% with AC followed by T, and 72.1% with FAC at 1 year (P = 0.002), and 66.7%, 73.3%, and 58.9%, respectively, at 3 years (P = 0.268). At one year, age (P

___
Source: http://www.hubmed.org/display.cgi?uids=18506620
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Toxicity of radiotherapy in patients with collagen vascular disease.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:52 AM
Subject: Toxicity of radiotherapy in patients with collagen vascular disease.
To: mesothelioma77@gmail.com


[1]Cancer. 2008 May 27;
Lin A, Abu-Isa E, Griffith KA, Ben-Josef E

BACKGROUND.: A diagnosis of collagen vascular disease (CVD) may predispose to radiotherapy (RT) toxicity. The objective of the current study was to identify factors that influence RT toxicity in the setting of CVD. METHODS.: A total of 86 RT courses for 73 patients with CVD were delivered between 1985 and 2005. CVD subtypes include rheumatoid arthritis (RA; 33 patients), systemic lupus erythematosus (SLE; 13 patients), scleroderma (9 patients), dermatomyositis/polymyositis (5 patients), ankylosing spondylitis (4 patients), polymyalgia rheumatica/temporal arteritis (4 patients), Wegener granulomatosis (3 patients), and mixed connective tissue disorders (MCTD)/other (2 patients). Each patient with CVD was matched to 1 to 3 controls with respect to sex, race, site irradiated, RT dose (+/-2 Gray), and age (+/-5 years). RESULTS.: There was no significant difference between CVD patients (65.1%) and controls (72.5%) experiencing any acute toxicity. CVD patients had a higher incidence of any late toxicity (29.1% vs 14%; P = .001), and a trend toward an increased rate of severe late toxicity (9.3% vs 3.7%; P = .079). RT delivered to the breast had increased risk of severe acute toxicity, whereas RT to the pelvis had increased risk of severe acute and late toxicity. RT administered in the setting of scleroderma carried a higher risk of severe late toxicity, whereas RT to SLE patients carried a higher risk of severe acute and late toxicity. CONCLUSIONS.: Although generally well tolerated, RT in the setting of CVD appears to carry a higher risk of late toxicity. RT to the pelvis or in the setting of SLE or scleroderma may predispose to an even greater risk of severe toxicity. These issues should be considered when deciding whether to offer RT for these patients. Cancer 2008. (c) 2008 American Cancer Society.



___
Source: http://www.hubmed.org/display.cgi?uids=18506734
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Mesothelioma Cancer Info

Unlike lung cancer, there is no association between mesothelioma and smoking In this disease, malignant cells develop in the mesothelium, a protective lining that covers transcendently of the body's internal organs. Its greatest simple site is the pleura (outer lining of the lungs and chest cavity), but it may also occur in the peritoneum (the lining of the abdominal cavity) or the pericardium (a sac that surrounds the heart).

Mesothelioma is a mastership of cancer that is almost always caused by previous exposure to asbestos

Mesothelial cells normally line the measurement cavities, including the pleura, peritoneum, pericardium, and testis. Malignant mesothelioma has a peak incidence 35-45 years after asbestos exposure.

Symptoms of peritoneal mesothelioma include weight loss and cachexia, abdominal swelling and pain due to ascites (a buildup of fluid in the abdominal cavity). If the cancer has size beyond the mesothelium to other parts of the measurement, symptoms may include aches and, trouble swallowing, or swelling of the neck or fall in with.

A physical examination is performed, followed by chest X-ray and often lung function tests. Symptoms of mesothelioma may not appear until 20 to 50 years after exposure to asbestos.  A history of exposure to asbestos may increase clinical suspicion for mesothelioma.

Other symptoms of peritoneal mesothelioma may include bowel obstruction, blood clotting abnormalities, anemia, and fever. Shortness of breath, cough, and suffering in the chest due to an accumulation of fluid in the pleural space are often symptoms of pleural mesothelioma.

Tissue is removed, placed under the microscope, and a pathologist makes a definitive diagnosis, and issues a pathology report.

Diagnosing mesothelioma is often difficult, because the symptoms are similar to those of a number of other conditions. Transcendently malignant mesotheliomas put complex karyotypes, with extensive aneuploidy and rearrangement of army chromosomes. Malignant mesothelioma is often just called simply Mesothelioma and is a skill of lung cancer that is quite rare. 

Malignant mesothelioma has also been linked to healing radiation using thorium dioxide and zeolite, a silicate in the soil.

Malignant mesothelioma is more direct in men, with a male-to-female ratio of 3:1. It can also occur in children; however, these cases are not thought to be associated with asbestos exposure.

Malignant mesothelioma is a rare type of cancer in which malignant cells are found in the sac lining the chest or abdomen. Most people with malignant mesothelioma require worked on jobs where they breathed asbestos.

Exposure to airborne asbestos particles increases one's risk of developing malignant mesothelioma.

Malignancies involving mesothelial cells in these length cavities are known as malignant mesothelioma, which may be localized or diffuse.

The 2 surgical procedures used are pleurectomy with decortication and extrapleural pneumonectomy.

Radiation has no effect on survival, but it has caused significant palliation in 50% of patients treated for chest suffering and chest wall metastasis. There are now a number of cancer treatment options available to mesothelioma patients. Extrapleural pneumonectomy for selected patients with very early stage disease may shape up recurrence-free survival, but the impact it has on overall survival is unknownat this time.

The desire of radiation therapy in pleural mesothelioma has been shown to ease pain in the majority of patients that are treated. But unfortunately, the duration of symptom control is short-lived. With surgery alone, the recurrence rate is very high and perfectly victims die after a few months. At least half the patients who have local control with surgery permit distant metastasis upon autopsy.

Mesothelioma Cancer an How Lives Are Affected

In this disease, malignant cells develop in the mesothelium, a protective lining that covers super of the length's internal organs. Its surpassingly unconfused site is the pleura (outer lining of the lungs and chest cavity), but it may also occur in the peritoneum (the lining of the abdominal cavity) or the pericardium (a sac that surrounds the heart).

 Malignancies involving mesothelial cells in these size cavities are known as malignant mesothelioma, which may be localized or diffuse. Mesothelioma is the word used to describe a cancerous tumor that involves the mesothelial cells of an organ, often the lungs, heart, or abdominal organs.

 

Mesothelioma is a savvy of cancer that is almost always caused by previous exposure to asbestos Malignant mesothelioma has also been linked to curing radiation using thorium dioxide and zeolite, a silicate in the soil.

 

 

Diagnosing mesothelioma is often difficult, because the symptoms are similar to those of a number of other conditions. Diagnosis begins with a review of the patient's medical history. Other symptoms of peritoneal mesothelioma may include bowel obstruction, blood clotting abnormalities, anemia, and fever. Shortness of breath, cough, and suffering in the chest due to an accumulation of fluid in the pleural space are often symptoms of pleural mesothelioma.

 Symptoms of peritoneal mesothelioma include weight loss and cachexia, abdominal swelling and aches and due to ascites (a buildup of fluid in the abdominal cavity).

 

Mesothelioma is diagnosed by pathological examination from a biopsy. Symptoms of mesothelioma may not appear until 20 to 50 years after exposure to asbestos. This is the end of a savvy that usually begins with symptoms that send most people to the doctor: a fluid build-up around the lungs (pleural effusions), shortness of breath, suffering in the chest, or pain or swelling in the abdomen.

 

Tissue is removed, placed under the microscope, and a pathologist makes a definitive diagnosis, and issues a pathology report. Malignant mesothelioma has a peak incidence 35-45 years after asbestos exposure. Transcendently people with malignant mesothelioma have on worked on jobs where they breathed asbestos. 

 

Malignant mesothelioma is often just called simply Mesothelioma and is a system of lung cancer that is quite rare. Malignant mesothelioma is more direct in men, with a male-to-female ratio of 3:1. Malignant mesothelioma is a rare type of cancer in which malignant cells are found in the sac lining the chest or abdomen. Most malignant mesotheliomas put complex karyotypes, with extensive aneuploidy and rearrangement of much chromosomes. It can also occur in children; however, these cases are not thought to be associated with asbestos exposure.

 

 

Exposure to airborne asbestos particles increases one's risk of developing malignant mesothelioma.

 Unlike lung cancer, there is no association between mesothelioma and smoking

 

The need for of radiation therapy in pleural mesothelioma has been shown to curtail pain in the majority of patients that are treated. But unfortunately, the duration of symptom control is short-lived. The 2 surgical procedures used are pleurectomy with decortication and extrapleural pneumonectomy.

 Radiation has no effect on survival, but it has caused significant palliation in 50% of patients treated for chest aches and and chest wall metastasis.

 

Surgical resection has been relied upon because radiation and chemotherapy require been ineffective absolute treatments. Pleurectomy with decortication is a more limited procedure and requires less cardiorespiratory reserve. It involves dissection of the parietal pleura, incision of the parietal pleura, and decortication of the visceral pleura followed by reconstruction. It has a morbidity rate of 25% and a mortality rate of 2%. It is a difficult procedure because the tumor encases the true to form pleura; the local recurrence rate is high.

Fwd: Randomized and Non-randomized Prospective Controlled Cohort Studies in Matched Pair Design for the Long-term Therapy of Corpus uteri Cancer Patients with a Mistletoe Preparation (Iscador).

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, May 24, 2008 at 11:22 PM
Subject: Randomized and Non-randomized Prospective Controlled Cohort Studies in Matched Pair Design for the Long-term Therapy of Corpus uteri Cancer Patients with a Mistletoe Preparation (Iscador).
To: mesothelioma77@gmail.com


[1]Eur J Med Res. 2008 Mar 31; 13(3): 107-20
Grossarth-Maticek R, Ziegler R

Background: Mistletoe preparations such as Iscador are in common use as complementary/anthropo?sophic medications for many cancer indications, particularly for solid cancers. Efficacy of this complementary therapy is still discussed controversially. - Objective: Does the long-term therapy with Iscador show any effect on survival or psychosomatic self-regulation of patients with corpus uteri cancer? - Patients and Methods: Prospective recruitment and long-term follow-up in the following 4 controlled cohort studies. (1) Two randomized matched-pairs studies: corpus uteri cancer patients without (30 pairs) and with distant metastases (26 pairs) that never used any kind of mistletoe therapy were matched for prognostic factors. By pairwise random allocation, one of the patients was suggested mistletoe therapy to be applied by the attending physician. (2) Two non-randomized matched-pairs studies: corpus uteri cancer patients without (103 pairs) and with distant metastases (95 pairs) that already received mistletoe (Iscador) therapy were matched by the same criteria to control patients without Iscador therapy. - Results: Concerning overall survival in the randomized studies, a significant effect in favour of Iscador therapy was present only in the first study, the second showed no evidence for an effect: estimate of the hazard ratio and 95% confidence interval: 0.36 (0.16, 0.82) and 1.00 (0.46, 2.16) respectively. In the non-randomized studies, the results that adjusted for relevant prognostic variables were: 0.41 (0.26, 0.63), and 0.61 (0.39, 0.93). The effect of therapy with Iscador within 12 months on psychosomatic self-regulation as a measure of autonomous coping with the disease shows a significant rise in the Iscador group against the control group in the randomized as well as in the non-randomized study on patients with corpus uteri cancer without metastases: estimate of the median difference and 95% confidence interval: 0.40 (0.15, 0.70) and 0.70 (0.25, 1.15) respectively. - Conclusion: The mistletoe preparation Iscador in these studies has the effect of prolonging overall survival of corpus uteri cancer patients. Psychosomatic self-regulation as a measure of autonomous coping with the disease, rises significantly more under Iscador therapy than under conventional therapy alone.



___
Source: http://www.hubmed.org/display.cgi?uids=18499556
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Malignant breast cancer in children: a review of 75 patients.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, May 24, 2008 at 11:22 PM
Subject: Malignant breast cancer in children: a review of 75 patients.
To: mesothelioma77@gmail.com


[1]J Surg Res. 2008 Jun 15; 147(2): 182-8
Gutierrez JC, Housri N, Koniaris LG, Fischer AC, Sola JE

OBJECTIVE: To determine incidence trends and outcomes for pediatric patients with malignant breast disease. METHODS: The Surveillance, Epidemiology, and End Results registry was examined for all females 19 years of age and younger diagnosed with a malignant breast tumor between 1973 and 2004. RESULTS: A total of 75 patients with malignant breast tumors were identified. Overall, 14.5% of patients had in situ tumors, and 85.5% had invasive disease. Tumors were classified as being either carcinomas (n = 41, 54.7%) or sarcomas (n = 34, 45.3%). The majority of sarcomatous lesions were phyllodes tumors (n = 29, 85.5%), whereas most carcinomas were of a ductal etiology (n = 19, 46.3%). The age-adjusted incidence of all malignant pediatric breast tumors in 2003 was 0.08 cases per 100,000 people (0.03 carcinoma and 0.06 sarcoma cases per 100,000 people). In the carcinoma group, regionally advanced disease was present in 11 patients (26.8%), whereas only 3 patients (7.3%) presented with metastatic disease. All patients with sarcomatous tumors presented with localized disease. Adjuvant radiation therapy was administered in only 9.8% of carcinomas and 8.8% of sarcomas, and 85.4% of carcinoma patients and 97.1% of sarcoma patients underwent surgical resection for their primary disease. Subgroup analysis revealed 5- and 10-year survival rates of 89.6% for patients with sarcomatous tumors and 63.1% and 54.3% for carcinomas. CONCLUSIONS: Malignant pediatric breast malignancies remain relatively rare. The two most common histologies of breast neoplasms in children are malignant carcinomas followed by sarcomas. Although uncommon, malignant disease must be considered in the differential diagnosis of the pediatric patient with a breast mass.



___
Source: http://www.hubmed.org/display.cgi?uids=18498867
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Methyl-donor nutrients inhibit breast cancer cell growth.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, May 24, 2008 at 11:23 PM
Subject: Methyl-donor nutrients inhibit breast cancer cell growth.
To: mesothelioma77@gmail.com


[1]In Vitro Cell Dev Biol Anim. 2008 May 23;
Park CS, Cho K, Bae DR, Joo NE, Kim HH, Mabasa L, Fowler AW

Lipotropes (methyl group containing nutrients, including methionine, choline, folate, and vitamin B(12)) are dietary methyl donors and cofactors that are involved in one-carbon metabolism, which is important for genomic DNA methylation reactions and nucleic acid synthesis. One-carbon metabolism provides methyl groups for all biological methylation pathways and is highly dependent on dietary supplementation of methyl nutrients. Nutrition is an important determinant of breast cancer risk and tumor behavior, and dietary intervention may be an effective approach to prevent breast cancer. Apoptosis is important for the regulation of homeostasis and tumorigenesis. The anti-apoptotic protein Bcl-2 may be a regulatory target in cancer therapy; controlling or modulating its expression may be a therapeutic strategy against breast cancer. In this study, the effects of lipotrope supplementation on the growth and death of human breast cancer cell lines T47D and MCF-7 were examined and found to inhibit growth of both T47D and MCF-7 cells. Furthermore, the ratios of apoptotic cells to the total number of cells were approximately 44% and 34% higher in the lipotrope-supplemented treatments of T47D and MCF-7 cancer cells, respectively, compared with the control treatments. More importantly, Bcl-2 protein expression was decreased by approximately 25% from lipotrope supplementation in T47D cells, suggesting that lipotropes can induce breast cancer cell death by direct downregulation of Bcl-2 protein expression. Cancer treatment failure is often correlated with Bcl-2 protein upregulation. These data may be useful in the development of effective nutritional strategies to prevent and reduce breast cancer in humans.



___
Source: http://www.hubmed.org/display.cgi?uids=18498022
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc